How many drugs treat Burkitt's lymphoma?

Drug Landscape tracks 10 marketed treatments for Burkitt's lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/burkitt-s-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Burkitt's lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Burkitt's lymphoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Burkitt's lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	vincristine	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	Alkylating agent	Tumor cell DNA	1959-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Trexall	methotrexate	Generic (originally Lederle Laboratories)	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in Burkitt's lymphoma
Pfizer Inc. · 2 drugs in Burkitt's lymphoma
University of Colorado, Denver · 2 drugs in Burkitt's lymphoma
Baxter · 2 drugs in Burkitt's lymphoma
Pfizer · 2 drugs in Burkitt's lymphoma
Johann Wolfgang Goethe University Hospital · 1 drug in Burkitt's lymphoma
Weill Medical College of Cornell University · 1 drug in Burkitt's lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 drug in Burkitt's lymphoma
Zhejiang University · 1 drug in Burkitt's lymphoma
Biocad · 1 drug in Burkitt's lymphoma
Chipscreen Biosciences, Ltd. · 1 drug in Burkitt's lymphoma
Generic (originally Lederle Laboratories) · 1 drug in Burkitt's lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Burkitt's lymphoma:

Cite this brief

Drug Landscape (2026). Burkitt's lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/burkitt-s-lymphoma. Accessed 2026-06-09.

Burkitt's lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing